Skip to content
Enterprise AI adoptionHTFL

HeartFlow (HTFL) AI Plaque Analysis Revenue: $11.8M in Q3 2026

Editorial illustration for HeartFlow (HTFL) AI Plaque Analysis Revenue: $11.8M in Q3 2026
Published 5 min read

Summary

HeartFlow reported AI plaque analysis revenue separately for the first time: $11.8 million in Q3, with a raised $36-37 million full-year outlook but no prior-period figure for growth.

On November 12, 2026, HeartFlow (HTFL) disclosed AI plaque analysis revenue as a separate figure for the first time on its third-quarter earnings call, reporting $11.8 million in product revenue and raising its full-year outlook [1]. The company did not disclose this product line's revenue for any earlier comparable period, so its own growth rate cannot yet be calculated.

What HeartFlow sells

Heartflow, Inc. Common Stock (HTFL) is a US cardiovascular imaging software company whose customers are mainly hospitals and imaging centers. After a patient has a coronary CT angiography (CCTA) scan, the images are uploaded to the HeartFlow platform, AI performs the analysis, and the results go to the cardiologist. Hospitals and imaging centers pay per case analyzed.

Plaque Analysis (PLAC) is one of the AI software products on that platform. It automatically measures the amount and composition of coronary plaque on CCTA images and converts plaque burden into a risk level, helping physicians judge how severe the disease is and decide whether to intensify treatment such as lipid-lowering drugs. It is a core product sold directly to customers. The company says it is applicable to approximately 60% of CCTA exams [1], which leaves room for wider use within each existing customer.

From clinical evidence to a revenue line in 2026

Public disclosures about Plaque Analysis in 2026 moved from clinical evidence to a reported revenue number.

  • March 18, 2026 (fourth-quarter 2025 call): The software was already in clinical use. Citing the DECIDE registry, the company said that compared with CCTA alone it changed physician management plans 51% of the time [2]. No revenue figure was given.
  • August 13, 2026: The company introduced plaque staging, which sorts the plaque burden measured by the software into four clinically distinct stages. It said the staging was validated in more than 23,000 patients with up to 16 years of follow-up [3]. This was a feature upgrade to the same workflow; the physicians served and the images analyzed did not change, and there was still no usage or revenue figure.
  • November 12, 2026 (third-quarter call): The chief financial officer reported Plaque Analysis revenue as its own line for the first time, so the application can now be measured by revenue.

Q3 2026 plaque analysis revenue and outlook

The $11.8 million is Plaque Analysis product revenue for the third quarter. It sits inside the quarter's $67.9 million of US revenue, and US revenue grew 60% year over year [1]. Based on the company's total quarterly revenue of about $72.9 million, Plaque Analysis was roughly 16% of the total.

Management also raised its full-year Plaque Analysis revenue outlook to $36 million to $37 million, said it expects about 1,300 activated accounts by year end, and said payer coverage for Plaque Analysis now reaches approximately 82% of US covered lives [1]. The company did not disclose Plaque Analysis revenue for the year-earlier quarter or the prior quarter. The figure shows the product's current scale; on its own it does not yield a growth rate.

How the AI shows up in the financials

The financial metric tied to this application is revenue (Plaque Analysis product revenue), followed by gross margin. Plaque Analysis is billed per case to hospitals and imaging centers, and that revenue flows directly into company sales. The company's separate disclosure of the figure confirms this link.

Gross margin rose from 76.8% to 83.8% in the quarter. Management listed a higher mix of Plaque Analysis revenue as one reason, alongside volume leverage and AI-driven production automation, but did not break out the specific contribution from Plaque Analysis.

Not all of the revenue growth can be credited to the algorithm itself. Broader payer coverage, new account activations and growth in CCTA volume are all pushing this revenue line higher.

Management also cited DECIDE registry results showing that patients managed with Plaque Analysis had 34% fewer major cardiovascular events within one year. That is a patient-level outcome from an observational study. It has not been tested in a randomized controlled trial, and it does not correspond to any figure in the company's financials.

What is established and what to track

What can be confirmed is that Plaque Analysis has moved from an AI tool whose value rested on clinical studies to a separately measured product line within HeartFlow's revenue. The company has not yet separately quantified the product's own growth rate, its contribution to gross margin, or how much of the increase comes from factors outside the algorithm, such as payer coverage and sales channels.

The next tests are whether fourth-quarter and full-year revenue land within the $36 million to $37 million range, whether activated accounts reach about 1,300, and whether the company provides a comparable year-over-year growth rate for the first time.

Application assessment

  • HeartFlow Plaque Analysis | Business role: core business | Deployment stage: limited production | Scope: single business unit | Value type: revenue growth

Sources

[1] Drillr · Heartflow, Inc. Common Stock (HTFL) · 2026-11-12 · Earnings call

"U.S. revenue grew to $67.9 million, up 60%, including $11.8 million of PLAC revenue."

[2] Drillr · Heartflow, Inc. Common Stock (HTFL) · 2026-03-18 · Earnings call

"DECIDE demonstrated that the heart flow plaque analysis changed physician management plans 51% of the time compared to CCTA alone."

[3] Drillr · Heartflow, Inc. Common Stock (HTFL) · 2026-08-13 · Earnings call

"Plaque staging translates the personalized disease burden itself into four clinically distinct stages. that help physicians assess the severity and guide medical management."

Related:HTFL

Want deeper analysis?

Ask drillr anything about HTFL — powered by SEC filings, earnings calls, and real-time data.

Try drillr.ai for free

drillr can make mistakes. Information only — not investment advice. Learn more